ProstAtak is a gene therapy commercialized by Candel Therapeutics, with a leading Phase III program in Prostate Cancer. According to Globaldata, it is involved in 11 clinical trials, of which 5 were completed, and 6 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ProstAtak’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ProstAtak is expected to reach an annual total of $217 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma. malignant glioma, pediatric malignant glioma including glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma and recurrent ependymomas, advanced non-metastatic pancreatic adenocarcinoma and prostate cancer. The therapeutic drug candidate consists of (AdV-tk) adenovirus-mediated expression of herpes simplex virus thymidine kinase and valacyclovir in combination with radiation therapy. AdV-tk is administered as intra-tumoral injection and valacyclovir is administered orally. It is developed based on the gene mediated cytotoxic immunotherapy (GMCI) technology.
Candel Therapeutics Overview
Candel Therapeutics, formerly Advantagene, is a biopharmaceutical company. It manufactures, develops, and tests cancer immunotherapy drugs and gene-based biologics. Candel Therapeutics offers CAN-2409 and CAN-3110, for the treatment of a broad range of solid tumor indications. It is focused on developing oncolytic viral immunotherapies for the treatment of cancer patients. The company’s oncolytic viral immunotherapy platforms use genetically engineered viruses to induce immunogenic death through viral-mediated cytotoxicity in cancer cells. Its products, CAN-3110 and CAN-2409 are used in the treatment of prostate cancer, brain cancer, pancreatic cancer, lung cancer, malignant pleural effusion, and mesothelioma. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.
The operating loss of the company was US$25.7 million in FY2021, compared to an operating loss of US$13.8 million in FY2020. The net loss of the company was US$36.1 million in FY2021, compared to a net loss of US$17.7 million in FY2020.
For a complete picture of ProstAtak’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.